TScan Therapeutics, Inc. Price, Forecast, Insider, Ratings, Fundamentals & Signals

Waltham, mass., april 24, 2024 (globe newswire) -- tscan therapeutics, inc. (nasdaq: tcrx), a clinical-stage biopharmaceutical company focused on the development of t cell receptor (tcr)-engineered t cell therapies (tcr-t) for the treatment of patients with cancer, today announced the acceptance of two abstracts for poster presentation at the upcoming 2024 american society of clinical oncology (asco) annual meeting being held may 31 – june 4 in chicago, il as well as virtually.

Waltham, mass., april 24, 2024 (globe newswire) -- tscan therapeutics, inc. (nasdaq: tcrx), a clinical-stage biopharmaceutical company focused on the development of t cell receptor (tcr)-engineered t cell therapies (tcr-t) for the treatment of patients with cancer, today announced that the underwriters of its previously announced public offering, which closed on april 19, 2024, have partially exercised their over-allotment option to purchase an additional 2,485,487 shares of its voting common stock at the public offering price of $7.13 per share, less underwriting discounts and commissions. after giving effect to the option closing, the total number of shares sold by the company in the offering were 4,958,068 shares, which along with pre-funded warrants to purchase up to an aggregate of 18,577,419 shares of its voting common stock, resulted in aggregate gross proceeds to the company of approximately $167...

Waltham, mass., april 22, 2024 (globe newswire) -- tscan therapeutics, inc. (nasdaq: tcrx), a clinical-stage biopharmaceutical company focused on the development of t cell receptor (tcr)-engineered t cell therapies (tcr-t) for the treatment of patients with cancer, today announced the acceptance of one abstract for oral presentation and four abstracts for poster presentation at the upcoming american society of gene and cell therapy (asgct) 27th annual meeting being held may 7-11 in baltimore, md as well as virtually.

Waltham, mass., april 19, 2024 (globe newswire) -- tscan therapeutics, inc. (nasdaq: tcrx), a clinical-stage biopharmaceutical company focused on the development of t cell receptor (tcr)-engineered t cell therapies (tcr-t) for the treatment of patients with cancer, today announced the closing of an underwritten public offering of 2,472,581 shares of its voting common stock at a public offering price of $7.1300 per share, which was equal to the closing price of its voting common stock on the nasdaq global market on april 16, 2024, and pre-funded warrants to purchase up to an aggregate of 18,577,419 shares of its voting common stock at a price to the public of $7.1299 per pre-funded warrant to purchase one share of the voting common stock, which represents the per share public offering price for the voting common stock less the $0...

Waltham, mass., april 17, 2024 (globe newswire) -- tscan therapeutics, inc. (nasdaq: tcrx), a clinical-stage biopharmaceutical company focused on the development of t cell receptor (tcr)-engineered t cell therapies (tcr-t) for the treatment of patients with cancer, today announced the pricing of an underwritten public offering of 2,472,581 shares of its voting common stock at a public offering price of the market price of $7.1300 per share, which was equal to the closing price of its voting common stock on the nasdaq global market on april 16, 2024, and pre-funded warrants to purchase up to an aggregate of 18,577,419 shares of its voting common stock at a price to the public of $7.1299 per pre-funded warrant to purchase one share of the voting common stock, which represents the per share public offering price for the voting common stock less the $0...

Generally speaking, you want to minimize your exposure to cheap stocks under $10. Yes, smaller companies have the potential to rise dramatically higher than their larger counterparts.

TScan Therapeutics, Inc. (TCRX) came out with a quarterly loss of $0.21 per share versus the Zacks Consensus Estimate of a loss of $0.30. This compares to loss of $0.78 per share a year ago.

All eight (100%) treatment-arm patients are relapse-free and have achieved and maintained complete donor chimerism following treatment with TSC-100 or TSC-101

TScan Therapeutics, Inc. (TCRX) saw its shares surge in the last session with trading volume being higher than average. The latest trend in earnings estimate revisions may not translate into further price increase in the near term.

Prevention relapse data from phase 1 study, using TSC-100/TSC-101 for HLA A*02:01 positive AML, MDS, and ALL patients, is expected to be released in 2024. Results from T-Plex [multiple TCR-Ts] targeting patients' solid tumors in phase 1 study are expected to be released in 2024. Amgen's multi-year collaboration deal brought in an upfront $30 million payment, $500 million possible milestone payments, and tiered royalties; First targeting Crohn's Disease and possibly later Ulcerative Colitis.

No relapses have occurred in six of six treatment-arm patients, four with follow-up past six months; one of four control-arm patients relapsed at six months and two others required clinical intervention

TScan Therapeutics, Inc. (TCRX) could be a great choice for investors looking to make a profit from fundamentally strong stocks that are currently on the move. It is one of the several stocks that made it through our "Recent Price Strength" screen.

The mean of analysts' price targets for TScan Therapeutics, Inc. (TCRX) points to a 62.3% upside in the stock. While this highly sought-after metric has not proven reasonably effective, strong agreement among analysts in raising earnings estimates does indicate an upside in the stock.

Does TScan Therapeutics, Inc. (TCRX) have what it takes to be a top stock pick for momentum investors? Let's find out.

TScan Therapeutics, Inc. (TCRX) made it through our "Recent Price Strength" screen and could be a great choice for investors looking to make a profit from stocks that are currently on the move.